Cargando…
A Unique Three-Way Variant Philadelphia Chromosome t(6;9;22)(p21.3;q34;q11.2) in a Newly Diagnosed Patient with Chronic Myeloid Leukemia Responded to Flumatinib
BACKGROUND: Chronic myeloid leukaemia (CML) is a clonal malignant disorder of a pluripotent hematopoetic stem cell characterized by the presence of Philadelphia (Ph) chromosome in more than 90% of patients. However, about 5–10% of CML patients show a variant Ph translocation, involving one or more c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509008/ https://www.ncbi.nlm.nih.gov/pubmed/36164408 http://dx.doi.org/10.2147/OTT.S377342 |
_version_ | 1784797141169864704 |
---|---|
author | Chen, Lili Zhang, Junling Yang, Na Tan, Ningping Meng, Di Zhang, Fei Qi, Yuyang Wu, Guangqi Li, Zhenyu |
author_facet | Chen, Lili Zhang, Junling Yang, Na Tan, Ningping Meng, Di Zhang, Fei Qi, Yuyang Wu, Guangqi Li, Zhenyu |
author_sort | Chen, Lili |
collection | PubMed |
description | BACKGROUND: Chronic myeloid leukaemia (CML) is a clonal malignant disorder of a pluripotent hematopoetic stem cell characterized by the presence of Philadelphia (Ph) chromosome in more than 90% of patients. However, about 5–10% of CML patients show a variant Ph translocation, involving one or more chromosomes in addition to 9 and 22. The treatment and prognostic impact of such additional abnormalities is not known. Herein, we report a unique case of a three-way translocation variant in CML and responded to flumatinib. CASE PRESENTATION: A 22-year-old Asian female who presented with leukocytosis was diagnosed with CML. Cytogenetic karyotyping analysis showed 46,XX,t(6;9;22)(p21.3;q34;q11.2). She was treated with flumatinib, and MR5.0 (BCR-ABL1 IS≤0.001%, international scale) was achieved after three months of continuous treatment. CONCLUSION: This was the 5th case of t(6;9;22), in particular, a new variant Ph translocation, and the first successful case treated with flumatinib in the world. |
format | Online Article Text |
id | pubmed-9509008 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-95090082022-09-25 A Unique Three-Way Variant Philadelphia Chromosome t(6;9;22)(p21.3;q34;q11.2) in a Newly Diagnosed Patient with Chronic Myeloid Leukemia Responded to Flumatinib Chen, Lili Zhang, Junling Yang, Na Tan, Ningping Meng, Di Zhang, Fei Qi, Yuyang Wu, Guangqi Li, Zhenyu Onco Targets Ther Case Report BACKGROUND: Chronic myeloid leukaemia (CML) is a clonal malignant disorder of a pluripotent hematopoetic stem cell characterized by the presence of Philadelphia (Ph) chromosome in more than 90% of patients. However, about 5–10% of CML patients show a variant Ph translocation, involving one or more chromosomes in addition to 9 and 22. The treatment and prognostic impact of such additional abnormalities is not known. Herein, we report a unique case of a three-way translocation variant in CML and responded to flumatinib. CASE PRESENTATION: A 22-year-old Asian female who presented with leukocytosis was diagnosed with CML. Cytogenetic karyotyping analysis showed 46,XX,t(6;9;22)(p21.3;q34;q11.2). She was treated with flumatinib, and MR5.0 (BCR-ABL1 IS≤0.001%, international scale) was achieved after three months of continuous treatment. CONCLUSION: This was the 5th case of t(6;9;22), in particular, a new variant Ph translocation, and the first successful case treated with flumatinib in the world. Dove 2022-09-20 /pmc/articles/PMC9509008/ /pubmed/36164408 http://dx.doi.org/10.2147/OTT.S377342 Text en © 2022 Chen et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Case Report Chen, Lili Zhang, Junling Yang, Na Tan, Ningping Meng, Di Zhang, Fei Qi, Yuyang Wu, Guangqi Li, Zhenyu A Unique Three-Way Variant Philadelphia Chromosome t(6;9;22)(p21.3;q34;q11.2) in a Newly Diagnosed Patient with Chronic Myeloid Leukemia Responded to Flumatinib |
title | A Unique Three-Way Variant Philadelphia Chromosome t(6;9;22)(p21.3;q34;q11.2) in a Newly Diagnosed Patient with Chronic Myeloid Leukemia Responded to Flumatinib |
title_full | A Unique Three-Way Variant Philadelphia Chromosome t(6;9;22)(p21.3;q34;q11.2) in a Newly Diagnosed Patient with Chronic Myeloid Leukemia Responded to Flumatinib |
title_fullStr | A Unique Three-Way Variant Philadelphia Chromosome t(6;9;22)(p21.3;q34;q11.2) in a Newly Diagnosed Patient with Chronic Myeloid Leukemia Responded to Flumatinib |
title_full_unstemmed | A Unique Three-Way Variant Philadelphia Chromosome t(6;9;22)(p21.3;q34;q11.2) in a Newly Diagnosed Patient with Chronic Myeloid Leukemia Responded to Flumatinib |
title_short | A Unique Three-Way Variant Philadelphia Chromosome t(6;9;22)(p21.3;q34;q11.2) in a Newly Diagnosed Patient with Chronic Myeloid Leukemia Responded to Flumatinib |
title_sort | unique three-way variant philadelphia chromosome t(6;9;22)(p21.3;q34;q11.2) in a newly diagnosed patient with chronic myeloid leukemia responded to flumatinib |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509008/ https://www.ncbi.nlm.nih.gov/pubmed/36164408 http://dx.doi.org/10.2147/OTT.S377342 |
work_keys_str_mv | AT chenlili auniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT zhangjunling auniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT yangna auniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT tanningping auniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT mengdi auniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT zhangfei auniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT qiyuyang auniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT wuguangqi auniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT lizhenyu auniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT chenlili uniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT zhangjunling uniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT yangna uniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT tanningping uniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT mengdi uniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT zhangfei uniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT qiyuyang uniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT wuguangqi uniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib AT lizhenyu uniquethreewayvariantphiladelphiachromosomet6922p213q34q112inanewlydiagnosedpatientwithchronicmyeloidleukemiarespondedtoflumatinib |